Linagliptin

Linagliptin

Systematic (IUPAC) name
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Clinical data
Trade names	Tradjenta, Trajenta
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a611036
Licence data	EMA:Link, US FDA:link
Pregnancy category	US: B (No risk in non-human studies)
Legal status	US: ℞-only
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	30% oral
Protein binding	75% to 99% in plasma
Identifiers
CAS Number	668270-12-0 Y
ATC code	A10BH05 (WHO)
PubChem	CID: 10096344
IUPHAR/BPS	6318
ChemSpider	8271879 N
UNII	3X29ZEJ4R2 Y
KEGG	D09566 Y
ChEMBL	CHEMBL237500 N
Chemical data
Formula	C25H28N8O2
Molecular mass	472.54 g/mol
SMILES CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
InChI InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1 N Key:LTXREWYXXSTFRX-QGZVFWFLSA-N N
NY (what is this?)  (verify)

Linagliptin (BI-1356, trade names Tradjenta (US), Trajenta (worldwide)) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.

Linagliptin (once-daily) was approved by the U.S. Food and Drug Administration (FDA) on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly.

Medical uses

Results in 2010 from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.

Side effects

They may cause severe joint pain.

Mechanism of action

Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output. Thus, linagliptin stimulates the release of insulin in a glucose-dependent manner and decreases the levels of glucagon in the circulation.

See also

• Glyxambi

External links

• Tradjenta official website (United States)
• Trajenta (Australia)
• Trajenta (Canada)
• Trajenta (European Union)
• Trajenta (India)